5-Amino-1MQ vs SLU-PP-332

5-Amino-1MQ

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide and depletes the cellular pool of S-adenosyl methionine (SAM), a critical methyl donor. By inhibiting NNMT, 5-Amino-1MQ is proposed to increase intracellular NAD+ levels and SAM availability, thereby enhancing cellular energy metabolism and epigenetic regulation. Research published by Neelakantan et al. The same research group at the University of Texas showed that NNMT expression is upregulated in visceral adipose tissue of obese subjects, suggesting the enzyme plays a direct role in metabolic dysfunction. Unlike GLP-1 receptor agonists that suppress appetite centrally, 5-Amino-1MQ operates at the cellular metabolic level by modulating the NAD+ salvage pathway and methylation balance, offering a mechanistically distinct approach. Compared to NMN or NR supplementation (NAD+ precursors), 5-Amino-1MQ addresses NAD+ depletion at the enzymatic level rather than through precursor loading. Studies also suggest NNMT inhibition may improve insulin sensitivity through modulated SIRT1 activity. Store lyophilized powder at -20C protected from moisture; reconstitute in sterile water. This compound is investigated by metabolic biochemistry laboratories, NAD+ biology researchers, and academic institutions studying the intersection of epigenetics and obesity.

SLU-PP-332

SLU-PP-332 is a synthetic small-molecule agonist of estrogen-related receptors (ERRs), specifically ERR-alpha, ERR-beta, and ERR-gamma. These orphan nuclear receptors regulate the transcription of genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid metabolism. Research from the Bhatt laboratory at Saint Louis University (published in ACS Chemical Biology, 2023) demonstrated that SLU-PP-332 use in mouse models increased exercise endurance and fatigue resistance without physical training, earning it attention as a potential exercise mimetic compound. The mechanism involves upregulating PGC-1alpha-dependent gene networks that modulate mitochondrial density and oxidative capacity in skeletal muscle. In ischemic stroke models, ERR activation by SLU-PP-332 has shown neuroprotective effects by preserving mitochondrial membrane integrity and reducing reactive oxygen species production (Willy et al., published in Cell Chemical Biology). Compared to other exercise mimetics such as AICAR (AMPK activator) or GW501516 (PPAR-delta agonist), SLU-PP-332 targets a distinct upstream transcriptional pathway that coordinately activates multiple metabolic gene programs rather than a single signaling cascade. Research also suggests potential applications in chronic fatigue and neurodegenerative conditions where mitochondrial dysfunction is implicated. Store lyophilized powder at -20C in a desiccated environment; reconstitute in DMSO or appropriate vehicle per study specifications. SLU-PP-332 is investigated by exercise physiology researchers, neuroscience departments studying metabolic neuroprotection, and pharmacology labs exploring nuclear receptor biology.

Frequently Asked Questions